Literature DB >> 9920504

Effects of a single local administration of cilostazol on neointimal formation in balloon-injured rat carotid artery.

N Ishizaka1, J Taguchi, Y Kimura, Y Ikari, T Aizawa, M Togo, K Miki, K Kurokawa, M Ohno.   

Abstract

To elucidate if locally administered cilostazol, an inhibitor of cyclic AMP phosphodiesterase III, suppresses neointimal formation in balloon-injured carotid artery of the rat, 20 mg of cilostazol was topically applied using pluronic gel at the time of balloon injury. Rats were sacrificed 14 days after balloon injury to measure the extent of neointimal formation. Plasma and tissue concentrations of cilostazol were also measured at 1, 3, 7 and 14 days after topical application. The 5-bromo-2'-deoxyuridine (BrdU, a thymidine analogue) was given intraperitoneally to detect proliferation of smooth muscle cells in the injured media at 3 days after balloon injury. At 1 day after injury, plasma and tissue concentrations were 0.147+/-0.043 microg/ml and 1380 microg/g tissue. Although the plasma concentration of cilostazol was undetectable ( < 0.02 microg/ml), a significant amount of cilostazol (46 microg/g tissue) was still detected in the tissue at the site of application even after 2 weeks. The intimal area of the injured carotid after 2 weeks was significantly smaller in the cilostazol-treated group than in the gel-treated control group (0.06+/-0.01 vs 0.15+/-0.02 mm2, P<0.001). BrdU-positive smooth muscle cells in the injured media after 3 days were also significantly fewer in the cilostazol-treated group than in the gel-treated control group (4.3+/-0.5 vs 9.1+/-0.9% of total cells, P < 0.001). These results suggest that local administration of cilostazol using pluronic gel maintains a high concentration of the drug at the application site, has an anti-proliferative effect on smooth muscle cells, and may have potential for clinical therapeutic use for the prevention of restenosis following arterial intervention.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9920504     DOI: 10.1016/s0021-9150(98)00147-6

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  11 in total

Review 1.  Anti-inflammatory therapies for atherosclerosis.

Authors:  Magnus Bäck; Göran K Hansson
Journal:  Nat Rev Cardiol       Date:  2015-02-10       Impact factor: 32.419

2.  Open-Label Phase I Clinical Study to Assess the Safety and Efficacy of Cilostazol in Patients Undergoing Internal Carotid Artery Stent Placement.

Authors:  Ameer E Hassan; Haralabos Zacharatos; Mikayel Grigoryan; Wondwossen G Tekle; Amir Khan; Farhan Siddiq; Gustavo J Rodriguez; Ramachandra Tummala; Bharathi Jagadeesan; M Fareed K Suri; Adnan I Qureshi
Journal:  Interv Neurol       Date:  2016-12-08

3.  Suppression of arterial intimal hyperplasia by cilostamide, a cyclic nucleotide phosphodiesterase 3 inhibitor, in a rat balloon double-injury model.

Authors:  Y Inoue; K Toga; T Sudo; K Tachibana; S Tochizawa; Y Kimura; Y Yoshida; H Hidaka
Journal:  Br J Pharmacol       Date:  2000-05       Impact factor: 8.739

4.  Cilostazol is anti-inflammatory in BV2 microglial cells by inactivating nuclear factor-kappaB and inhibiting mitogen-activated protein kinases.

Authors:  Won-Kyo Jung; Da-Young Lee; Cheol Park; Yung Hyun Choi; Inhak Choi; Sae-Gwang Park; Su-Kil Seo; Soo-Woong Lee; Sung Su Yea; Soon-Cheol Ahn; Chang-Min Lee; Won Sun Park; Jae-Hong Ko; Il-Whan Choi
Journal:  Br J Pharmacol       Date:  2010-01-28       Impact factor: 8.739

Review 5.  Drug treatment of intermittent claudication.

Authors:  Douglas Jacoby; Emile R Mohler
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 6.  The vascular effects of cilostazol.

Authors:  William S Weintraub
Journal:  Can J Cardiol       Date:  2006-02       Impact factor: 5.223

7.  Study design and rationale of "Synergistic effect of combination therapy with cilostazol and ProbUcol on plaque stabilization and lesion REgression (SECURE)" study: a double-blind randomised controlled multicenter clinical trial.

Authors:  Young-Guk Ko; Byeong-Keuk Kim; Byoung Kwon Lee; Woong Chol Kang; Seung Hyuk Choi; Sang Wook Kim; Jong Ho Lee; Myoungsook Lee; Yasuhiro Honda; Peter J Fitzerald; Won-Heum Shim
Journal:  Trials       Date:  2011-01-12       Impact factor: 2.279

8.  Cilostazol activates function of bone marrow-derived endothelial progenitor cell for re-endothelialization in a carotid balloon injury model.

Authors:  Rie Kawabe-Yako; Masaaki Ii; Ii Masaaki; Osamu Masuo; Takayuki Asahara; Toru Itakura
Journal:  PLoS One       Date:  2011-09-12       Impact factor: 3.240

9.  Cilostazol inhibits accumulation of triglyceride in aorta and platelet aggregation in cholesterol-fed rabbits.

Authors:  Hideki Ito; Kenji Uehara; Yutaka Matsumoto; Ayako Hashimoto; Chifumi Nagano; Manabu Niimi; Goro Miyakoda; Keisuke Nagano
Journal:  PLoS One       Date:  2012-06-22       Impact factor: 3.240

10.  Combined therapeutic effect of probucol and cilostazol on endothelial function in patients with silent cerebral lacunar infarcts and hypercholesterolemia: a preliminary study.

Authors:  Bonpei Takase; Masayoshi Nagata; Hidemi Hattori; Yoshihiro Tanaka; Masayuki Ishihara
Journal:  Med Princ Pract       Date:  2013-11-09       Impact factor: 1.927

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.